FDA Brief

Warning letters Drugs

FDA warning letter to

New England Life Care, Inc. dba Advanced Compounding Solutions

High riskIssued May 16, 2023Posted May 30, 2023Division of Pharmaceutical Quality Operations I

FDA cites Advanced Compounding Solutions for insanitary sterile-drug production and CGMP failures after a 2022 inspection.

What happened

FDA inspected the Woburn, MA outsourcing facility from March 21 to April 28, 2022. Investigators found sterile drugs made under insanitary conditions—such as operators resting hands on a hood work surface, blocked first air, inadequate smoke studies, hard-to-clean surfaces, liquid pools, pests, and blocked air returns—plus CGMP (current good manufacturing practice) failures in investigations, complaints, cleaning, and air supply. The company also omitted dosage form on labels for several compounded drugs.

What FDA found

  1. Sterile drug products were prepared under insanitary conditions that could contaminate them, including poor aseptic technique, blocked first air, pests, and liquid on cleanroom floors.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The firm failed to thoroughly investigate unexplained discrepancies or batch failures.

    21 CFR 211.192
  3. The firm failed to establish and follow adequate complaint-handling procedures and did not investigate a cited complaint.

    21 CFR 211.198(a)
  4. The firm failed to establish and follow written procedures to prevent microbiological contamination, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  5. The firm failed to establish an adequate system for cleaning and disinfecting rooms and equipment used for aseptic conditions.

    21 CFR 211.42(c)(10)(v)
  6. The firm failed to provide an adequate air supply filtered through high-efficiency particulate air (HEPA) filters under positive pressure in aseptic processing areas.

    21 CFR 211.42(c)(10)(iii)

What FDA wants

FDA tells the company to promptly correct the violations, investigate their causes, and prevent recurrence, and strongly recommends a comprehensive assessment of its aseptic operations by a third-party sterile drug manufacturing expert. No response deadline is stated in the provided letter.

Who should pay attention

  • other 503B outsourcing facilities making sterile drugs
  • hospitals and clinics that buy compounded sterile products
  • compounding pharmacy quality teams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk